Finasteride, a competitive inhibitor of the 5? reductase enzyme which is used in the treatment of benign prostatic hyperplasia. It is selective for 5? reductase type 2 enzyme and has no affinity for androgen receptors. The development of the prostate gland and subsequent BPH is dependent upon conversion of testosterone to dihydrotestosterone (DHT) within the prostate. Finasteride belongs to a new class of specific inhibitors of 5? reductase, an intracellular enzyme, which metabolises testosterone into the more potent androgen, DHT. Finasteride has no affinity for the androgen receptor.
Finasteride (For B.P.H.)
(in Tablet form)
The recommended dosage is one 5 mg tablet daily. Although early improvement may be seen, treatment for at least six months may be necessary to assess whether a beneficial response has been achieved. Thereafter, treatment should be continued.
Manufacturer: Square Pharmaceutical Ltd.